$0.67
-0.01 (-1.23%)
Open$0.69
Previous Close$0.68
Day High$0.70
Day Low$0.67
52W High$27.04
52W Low$0.62
Volume—
Avg Volume38.3K
Market Cap2.57M
P/E Ratio—
EPS$-63.54
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+7,148.5% upside
Current
$0.67
$0.67
Target
$48.34
$48.34
$29.39
$48.34 avg
$58.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.75M | 1.85M | 1.56M |
| Net Income | -488,923 | -548,272 | -518,591 |
| Profit Margin | -27.9% | -29.7% | -33.3% |
| EBITDA | -843,788 | -899,520 | -655,593 |
| Free Cash Flow | -343,922 | -223,177 | -234,743 |
| Rev Growth | +4.0% | +6.5% | +13.9% |
| Debt/Equity | 0.91 | 0.97 | 0.83 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |